Undisclosed RA targeted cell therapy / MaxCyte - LARVOL DELTA

High efficiency complex gene editing of hard-to-transfect primary cells using MaxCyte electroporation in combination with Synthego sgRNAs (ESGCT 2024) - "Cell-based therapeutics using engineered primary cells hold great promise for treating a variety of diseases, including cancer and autoimmune disorders...Here, we show that using MaxCyte electroporation to deliver Synthego CRISPR gene editing tools as part of a cell therapy manufacturing process enables efficient and reproducible gene editing across a variety of cell engineering workflows. We show that this cell engineering strategy is suitable for use in many of the hard-to-transfect primary human cell types – including primary human T cells, NK cells, keratinocytes, and macrophages – that are increasingly being used in the development of next-generation cell therapies."

Combination therapy • Immunology

Selecting a Cell Engineering Methodology During Cell Therapy Product Development. (PubMed, Cell Transplant) - "This review covers important topics for mapping out a strategy for developers of new cell-based therapeutics. Biological, technological, manufacturing, and clinical considerations are all presented to map out development lanes for the initiation and risk management of new gene-based cell therapeutic products for human use."

Journal • Gene Therapies • Transplantation